A dsm-firmenich apresenta os primeiros resultados mundiais comparando sua nova formulação de CBD CBtru® com o Epidiolex.
Esse estudo clínico de Fase I mostra que o CBtru® oferece biodisponibilidade equivalente ou melhor do que o padrão ouro atual, com menor variabilidade entre os indivíduos e menor dependência alimentar. Esse avanço na formulação sólida pode transformar a administração de medicamentos com CBD com opções de dosagem mais convenientes e melhor experiência do paciente.
Palestrante:
Essa sessão tem duração de 20 minutos.
Discover how dsm-firmenich and ten23 health are transforming biologic formulation development through advanced excipient options.
Explore what newly published CBtru® pharmacokinetic data means for solid oral drug development—and why clinical evidence underpins meaningful innovation.
Discover how pharmaceutical quality management is advancing through proactive strategies that reduce risk, improve visibility, and support compliance.
Have an idea for a new project, a groundbreaking innovation, or a need for expert services? Let’s talk.
Don’t just take our word for it. Discover how our solutions can support your product development journey.
Customized blends of functional ingredients in one single, efficient premix.
Streamline your product development process and get to market faster.
From trade shows to conferences and other industry events, find out where you can meet us next.
Talking Nutrition, Health & Care
Explore new science, consumer insights, industry news and more in our latest articles.
Discover educational whitepapers, webinars, publications and technical information.
Request samples, place orders and view product documentation.